Skip to main content
Equibles

Verition Fund Management LLC

Position in RXRX — Recursion Pharmaceuticals, Inc.

CIK 1454027 GREENWICH, CT
Back to RXRX Full portfolio

Position in RXRX

as of Jun 30, 2026 · filed Aug 14, 2026
Position Value
$1,640,295
+$373,162 QoQ
Shares Held
446,947
+8.3% QoQ
Ownership
0.083%
of shares outstanding
% of Portfolio
0.01%
of 13F equity value
Holder Rank
#57
of 344 holders
Holding Since
Mar 2023
7 quarters on record
Voting authority Sole 100% Shared 0% None 0%

Common Shares in RXRX Over Time

Shares Held

Position Value (USD)

Derivatives in RXRX

reported options exposure · as of Jun 30, 2026
CallValue
$0
CallShares
0
PutValue
$1,619,938
PutShares
441,400

Notional value of option positions as reported on Form 13F. Calls and puts are disclosed separately and do not net against the common-share stake above.

Position in Biotechnology

Healthcare · as of Jun 30, 2026

Verition Fund Management LLC holds $156,064,619 across 65 Biotechnology names. RXRX ranks #21 (1.1% of the industry book) .

# Ticker Company Shares Value (USD) Open
1 TECH
BIO-TECHNE Corp
 438,746 $30,997,404
2 APGE
Apogee Therapeutics, Inc.
 159,256 $21,138,048
3 ABVX
Abivax S.A.
 105,791 $14,097,708
4 IDYA
IDEAYA Biosciences, Inc.
 184,054 $6,859,692
5 SNDX
Syndax Pharmaceuticals Inc
 304,939 $6,665,966
6 MRVI
Maravai Lifesciences Holdings, Inc.
 777,738 $4,853,085
7 CYTK
Cytokinetics Inc
 54,889 $4,675,993
8 RPRX
Royalty Pharma plc
 75,000 $4,205,250

All Filings in RXRX

Export CSV
14 filing rows on record
Report Date Value (USD) Shares
2026-06-30 $1,619,938 441,400
2026-06-30 $1,640,295 446,947
2026-03-31 $1,267,133 412,747
2026-03-31 $1,245,499 405,700
2025-12-31 $1,688,135 412,747
2025-12-31 $1,659,313 405,700
2025-09-30 $2,063,264 422,800
2025-09-30 $266,340 54,578
2025-09-30 $2,228,696 456,700
2025-06-30 $1,376,320 272,000
2025-06-30 $1,265,000 250,000
2025-06-30 $1,129,472 223,216
2025-03-31 $579,323 109,513
2023-03-31 $222,778 33,400